



European Society of
Gynaecological Oncology

ESGO Patient Seminar

Milan, Italy – September 11, 2011, 10:00-17:15

Milan Convention Center, Hall E / Yellow Hall



Dear Participants,

For the first time, ESGO is organising a seminar for European patient groups with an interest in gynaecological cancers. The seminar will focus on the 'silent' gynaecological cancers, specifically ovarian, endometrial, cervical and vulvar cancers. These cancers are silent because they do not attract attention from the public and policy makers; women themselves may be unaware of the sometimes vague symptoms or may be too embarrassed to talk to a doctor; and wide inequalities exist depending on where patients live and are treated within Europe.

The final session of the seminar will focus on building alliances across organisations and groups, working to have a stronger European voice and to generate collaboration in bridging inequalities at local levels.

During and after the seminar there will be a process of identifying leaders within the group and individual discussion about building a coalition.

We would like to extend a heartfelt thank-you to the sponsors for their generous support and genuine interest in this topic, the speakers for sharing their knowledge and experiences which will help us make informed decisions and to all the participants who have come to Milan to learn, share information and best practice. We believe that by building leadership and alliances, we can give the 'silent' gynaecological cancers a common voice, giving women in Europe hope that no matter where they live, access to timely and quality information, including early detection, diagnosis and treatment is a right and not a privilege.

A handwritten signature in black ink, appearing to read 'Ate G. J. van der Zee'.

Ate G. J. van der Zee
Co-Chair, ESGO Patient
Seminar
President, ESGO

A handwritten signature in black ink, appearing to read 'Louise Bayne'.

Louise Bayne
CEO, Ovacome
Co-Chair, ESGO Patient
Seminar

Four sessions with presentations and discussions:

The Patient Perspective: Gynaecological Cancer in Europe

Seminar Co-chairs: Ate GJ van der Zee, ESGO President; Louise Bayne, Ovacom

Format: Four sessions with presentations and discussions

Time	Session title
10:00-11:00	Session 1: Setting the scene
11:00-11:15	Coffee break
11:15-12:45	Session 2: Innovation in treating gynaecological cancers
12:45-13:45	Lunch break
14:00-15:15	Session 3: Sharing best practice in patient driven initiatives
15:15-16:00	Workshop: Collaboration across Gynaecological Cancer Patient Groups & Conclusions
16:00-16:20	Coffee break
16:20-16:55	Workshop continued: Collaboration across Gynaecological Cancer Patient Groups & Conclusions
16:55-17:15	Session 4: The way forward and close

Session 1: Setting the Scene:

Gynaecological cancer and inequalities

Chair: Ate G. J. van der Zee, ESGO President, The Netherlands

Aim: Understand the breadth of common and rare gynaecological cancers, as well as inequalities in their treatment and care

Presentations:

1. Inequalities in survival of (gynaecological) cancers in Europe today. *Speaker:* John Butler, International Cancer Benchmarking Partnership, Gynaecological Oncology Fellow St Bartholomew's and Royal Marsden Hospitals, UK
2. Discussion with audience

Session 2: Innovation in treating gynaecological cancers & improving outcomes

Chair: Flavia Bideri, ACTO onlus, Italy

Aim: Discuss innovation and multidisciplinary in gynaecological cancer treatment.

Presentations:

1. Innovation, target therapies and individualized medicine: What are the new trends and what about following guidelines vs. individualized treatment? *Speaker:* Frederic Amant, Department of Obstetrics & Gynaecology, UZ Gasthuisberg / Katholieke Universiteit Leuven, Belgium

2. Current options and the ongoing future of clinical trials? *Speaker:* Jalid Sehouli, Charité Universitätsmedizin Berlin, Germany
3. Multidisciplinary treatment in gynaecologic cancer – how do we bridge the gaps between surgery, radiotherapy, medical oncology and nursing to serve patients holistically? *Speaker:* Emma Elliott, National Forum of Gynaecological Oncology Nurses
4. Patient Participation and research: how patient groups contribute to clinical research. *Speaker:* Flavia Bideri, ACTOonlus, Italy
5. Discussion with audience: How can patient groups engage in cancer?

Session 3: Best practice in patient-driven initiatives

Chair: Jan Geissler, CEO Patvocates and Co-Founder CML Advocates Network

Aim: Learn from inspiring success stories of patient advocacy groups.

Presentations:

1. Best practice from patient and other groups:
 - a. Ovacom (leading initiatives in Ovarian cancer); *Speaker:* Louise Bayne, Ovacom, UK
 - b. PATH – Patient-driven breast cancer tumor bank (is the PATH tumor bank a role model for other gynaecological cancers?) *Speaker:* Doris Schmitt, PATH, Germany

- c. From patient literacy to advocacy. *Speaker:* Paola Mosconi, Istituto di Ricerche Farmacologiche Mario Negri, Italy
2. Discussion with audience: How can we learn more from each other and share best practice, replicating success stories?

Workshop: Collaboration across Gynaecological Cancer Patient Groups

Chair: Louise Bayne, CEO Ovacom, UK

Aim: We need to consider the benefits of collaboration between gynaecological cancer patient groups in Europe and how joining forces on issues that are common to the groups across these disease areas can lead to improvements at the local and European level.

1. Panel discussion: Effecting change by indication or a common voice: Does the gynaecological cancer community need to join forces?
2. Group discussion: The next steps

Session 4: The way forward and close

Aim: Discuss potential benefits of collaboration between gynaecological patient groups in Europe and how this can improve patient care on the local and EU level

Chair: Nicoletta Colombo, President-elect, ESGO, Italy



About ESGO: The European Voice of Gynaecological Oncology!

The European Society of Gynaecological Oncology (ESGO) is the principal European society of gynaecological oncology contributing to the study, prevention and treatment of gynaecological cancer. Today, ESGO has members in over 30 countries in Europe.

ESGO's mission:

ESGO strives to improve the health and well-being of European women with gynaecological (genital and breast) cancer through prevention, excellence in care, high quality research and education.

Together with the International Gynecologic Cancer Society (IGCS), ESGO publishes the bi-monthly International Journal of Gynecological Cancer (IJGC) – a highly popular journal covering topics, including basic science, epidemiology, diagnostic techniques, surgery, radiotherapy, chemotherapy, pathology and experimental studies.

Contact us:

ESGO Administrative Office, c/o Kenes International,
1-3 rue de Chantepoulet, PO Box 1726, CH-1211 Geneva - Switzerland,
Tel: +41 22 906 91 71, Fax +41 22 732 26 07,
E-Mail: adminoffice@esgo.org, **Web: www.esgo.org**

As a leading oncology society, ESGO holds a biennial meeting where 2400 experts meet to discuss the latest advances in gynaecological treatment and care. ESGO, together with the European Board & College of Obstetrics and Gynaecology (EBCOG), set up the European standards of training in gynaecological cancer and provides accreditation of European training centres in excellence in gynaecological oncology. ESGO also holds numerous workshops throughout the calendar year, provides clinical and research grants and fellowships, different online educational materials, webcasts and numerous networking possibilities to members. ESGO also provides certification of European training centres in excellence in gynaecological oncology and accredits individual accredited training of gynaecological oncologists.

We would like to take this opportunity to thank our lead sponsors for their generous support of the ESGO Patient Seminar.

